Question 1Response 1-cost leadershipArcoda adopted the cost leadership strategy as a way to gain an advantage over its competitors. It did this by rolling out a restructuring plan in 2017, that was meant to reduce its costs significantly. Personnel reduction was decided as the single most relevant cost reductiontactic, which would aid the company to achieve its new goals.Acorda reduced its total staff by 20% (Alvarez‐Garrido and Dushnitsky, 2016). The money was redirected to fund the advancement of two of its product lines that had potential to be very lucrative for the company that is the CVT-301, that is meant for late stage or phase 3 of Parkinson's disease and tozadenant. According to Martin (2015), the potential for growth from the focus on these two product lines was tremendous, and Ron Cohen, the president and the CEO of Acorda attested to that.ReferencesAlvarez‐Garrido, E., & Dushnitsky, G. (2016). Are entrepreneurial venture's innovation rates sensitive to investor complementary assets? Comparing biotech ventures backed by corporate and independent VCs. Strategic Management Journal, 37(5), 819-834.Martin, P. (2015). Commercializing neuro futures: Promissory economies, value creation and the making of a new industry. BioSocieties, 10(4), 422-443Question 1Response 2-DifferentiationOrganizations need to find out which